Lilly sues six companies over unapproved retatrutide sales
Six lawsuits over unapproved retatrutide focus on sellers of a drug with no approved form and no compounding exception.
Eli Lilly filed six federal lawsuits on Aug. 12, 2026, against businesses it accuses of illegally selling retatrutide, the company's experimental weight-loss drug that has not been approved by the FDA or any other regulator in the world [1][2]. The defendants are four "research-use-only" peptide sellers, one medical spa and one compounding pharmacy, and the cases were filed in four different federal district courts in Texas [1].
In each suit, Lilly seeks a permanent injunction barring the defendant from manufacturing, marketing, distributing, dispensing or selling any product containing or purporting to contain retatrutide, along with disgorgement of profits and attorney's fees [1].
Retatrutide is a triple hormone agonist that targets GLP-1, GIP and glucagon receptors, and it is in Phase 3 clinical trials [1]. Lilly plans to submit it for FDA approval in early 2027 [2]. Because no version is approved, it can only be accessed through Lilly-sponsored clinical trials or, in narrow circumstances, the FDA's expanded access framework [1]. Lilly set up a formal expanded access program and told Becker's on Aug. 4 that authentic retatrutide could be made available before approval to a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial [2].
The FDA has stated that retatrutide "cannot be used in compounding under federal law" [1]. Retatrutide has never been in shortage, so the shortage-based compounding exceptions under Sections 503A and 503B of the Food, Drug, and Cosmetic Act have never applied to it [1]. It is not a component of an FDA-approved drug, does not appear on the FDA's list of bulk drug substances that may be compounded, and lacks a USP or NF monograph [1]. That makes these cases different from earlier disputes over compounded semaglutide and tirzepatide, which were approved drugs and were in shortage at the relevant times [1].
Most of Lilly's claims rely on state unfair competition and consumer protection laws, citing statutes in Texas, Tennessee, Washington, North Carolina, South Carolina, Colorado, Connecticut and Alaska [1]. The complaints do not assert patent infringement. The only federal false-advertising claim under the Lanham Act is against Aesthetic Envy, a med spa, for allegedly advertising its "Triple G" therapies on its website and social media [1]. The four research-use-only sellers labeled their products for laboratory use while marketing them in ways Lilly alleges were directed at human use, according to the complaints [1]. The suit against the pharmacy alleges it sold retatrutide to medical spas and providers [1]. Lilly said these businesses "are not practicing medicine; they are selling illegal drugs," and contends that unregulated products may be fake, impure or mis-dosed [1].
Lilly reports it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards, and has flagged more than 14,000 websites, advertisements, social media posts and product listings in more than 100 countries [1][2]. The company is calling on regulators, law enforcement, social media and e-commerce platforms, payment companies and shipping companies to act against sales of unapproved retatrutide [2].
Why it matters for patients
There is no lawful retail, pharmacy or wellness distribution channel for retatrutide in the United States [1]. A product sold online or administered at a med spa is not an FDA-approved medicine, and a "research use only" label does not change that [1].
Because no approved retatrutide product exists, there is no FDA-reviewed manufacturing standard, no approved dose and no assurance about what is in a vial; Lilly alleges the products it sued over may be fake, impure or mis-dosed [1].
The history of compounded semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) does not carry over here. Those drugs were approved and were on the FDA's shortage list, which created a temporary compounding pathway. Retatrutide has never been approved and has never been in shortage, so no such pathway has existed [1].
One unresolved question is whether retatrutide will be regulated as a drug or as a biological product. Lilly has challenged an FDA determination on that point, and a federal court vacated and remanded part of the agency's decision about whether retatrutide is "analogous" to a protein [1]. If it is regulated as a biological product under Section 351 of the Public Health Service Act, the usual 503A and 503B compounding exemptions would not provide a pathway for compounded copies [1].
What happens next
Lilly filed the six lawsuits on Aug. 12, 2026, and is seeking permanent injunctions [1]. No rulings or settlements in these cases have been reported.
Lilly plans to submit retatrutide for FDA approval in early 2027 [2]. The expanded access program announced in August 2026 remains limited to patients who meet specific medical criteria and cannot join a clinical trial [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.